Related Experiment Video
Updated: Sep 5, 2025
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.4K
Will Proton Pump Inhibitors Increase the Risk of Diabetes Mellitus? A Systemic Review and Meta-Analysis
Yue Chen1, Lei Hu1, Chenyu Sun2
1Department of Clinical Medicine, School of the First Clinical Medicine, Anhui Medical University, Hefei, Anhui, China.
Summary
Proton pump inhibitor (PPI) use does not appear to increase or decrease diabetes mellitus risk. Further research is needed to clarify the association in diverse populations.
Area of Science:
- Gastroenterology
- Endocrinology
- Pharmacology
Background:
- Proton pump inhibitors (PPIs) are widely used medications.
- Previous reports suggested potential benefits of PPIs in diabetes mellitus prevention.
- The association between PPI use and diabetes mellitus risk requires thorough investigation.
Purpose of the Study:
- To systematically investigate the association between proton pump inhibitor use and the risk of developing diabetes mellitus.
Main Methods:
- A systematic literature search identified eligible studies up to February 2021.
- Quality assessment used Jadad Scoring and Newcastle-Ottawa Scales.
- Meta-analysis calculated pooled hazard ratios with 95% CIs using random- or fixed-effects models.
Main Results:
- Eight studies with 850,019 participants were included.
- PPI use showed a non-significant increased risk of diabetes mellitus (HR 1.06, 95% CI 0.89-1.28).
- Subgroup analyses revealed significant increased risk in Europe and decreased risk in Asia, contrasting with North American studies.
Conclusions:
- Proton pump inhibitor use is not definitively associated with altered diabetes mellitus risk.
- Further high-quality studies are necessary, particularly in diverse populations, to elucidate this relationship.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
247
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
247
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
283
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
283
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
521
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
521
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
251
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
251
01:22Diabetes Mellitus: Type 2 and Gestational
2.8K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.8K
01:20Pathophysiology of Diabetes
1.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.2K